Pro Inflammatory Cytokines Profiles of Patients With Long COVID Differ Between Variant Epochs
Journal of Primary Care & Community Health · 2024
DOI: 10.1177/21501319241254751 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Primary Care & Community Health, 2024. Verfasst von Ravindra Ganesh und 13 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Cytokines, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, GHR Foundation.
Abstract (Originalsprache)
Background
Over 30% of patients with COVID-19 have persistent symptoms that last beyond 30 days and referred to as Long COVID. Long COVID has been associated with a persistent elevation in peripheral cytokines including interleukin-6, interleukin-1β, and tumor necrosis factor-α. This study reports cytokine profiles of patients in our clinic across SARS-COV-2 variant epochs.
Methods
The clinical cytokine panel was analyzed in patients with Long COVID during periods that were stratified according to variant epoch. The 4 variant epochs were defined as: (1) wild-type through alpha, (2) alpha/beta/gamma, (3) delta, and (4) omicron variants.
Results
A total of 390 patients had the clinical cytokine panel performed; the median age was 48 years (IQR 38-59) and 62% were female. Distribution by variant was wild-type and alpha, 50% (n = 196); alpha/beta/gamma, 7.9% (n = 31); delta, 18% (n = 72); and omicron, 23% (n = 91). Time to cytokine panel testing was significantly longer for the earlier epochs. Tumor necrosis factor-α ( P < .001) and interleukin 1β ( P < .001) were significantly more elevated in the earlier epochs (median of 558 days in wild-type through Alpha epoch vs 263 days in omicron epoch, P < .001)). Nucleocapsid antibodies were consistently detected across epochs.
Discussion
When stratified by variant epoch, patients with early epoch Long COVID had persistently elevated peripheral pro-inflammatory cytokine levels when compared to later epoch Long COVID. Patients with Long COVID have similar clusters of symptoms across epochs, suggesting that the underlying pathology is independent of the peripheral cytokine signature.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mayo Clinic, Rochester, MN, USA.
ORCID-Profile: Ravindra Ganesh, Stephanie L Grach, Ivana T Croghan
Förderung
- NIAID NIH HHS
- GHR Foundation
Zitieren
APA
Ganesh, R., Yadav, S., Hurt, R. T., Mueller, M. R., Aakre, C. A., Gilman, E. A., Grach, S. L., Overgaard, J., Snyder, M. R., Collins, N. M., Croghan, I. T., Badley, A. D., Razonable, R. R., & Salonen, B. R. (2024). Pro Inflammatory Cytokines Profiles of Patients With Long COVID Differ Between Variant Epochs. Journal of Primary Care & Community Health. https://doi.org/10.1177/21501319241254751
Vancouver
Ganesh R, Yadav S, Hurt RT, Mueller MR, Aakre CA, Gilman EA, et al. Pro Inflammatory Cytokines Profiles of Patients With Long COVID Differ Between Variant Epochs. Journal of Primary Care & Community Health. 2024. doi:10.1177/21501319241254751
BibTeX
@article{Ganesh2024,
author = {Ganesh, Ravindra and Yadav, Siddhant and Hurt, Ryan T and Mueller, Michael R and Aakre, Christopher A and Gilman, Elizabeth A and Grach, Stephanie L and Overgaard, Joshua and Snyder, Melissa R and Collins, Nerissa M and Croghan, Ivana T and Badley, Andrew D and Razonable, Raymund R and Salonen, Bradley R},
title = {Pro Inflammatory Cytokines Profiles of Patients With Long COVID Differ Between Variant Epochs},
journal = {Journal of Primary Care & Community Health},
year = {2024},
doi = {10.1177/21501319241254751}
}
EUVIMED